O steoporosis and thyroid dysfunction are both common in older women; 8% to 13% of women older than 50 years of age have biochemical evidence of thyroid dysfunction (1, 2) , and 30% are osteoporotic according to bone density criteria (3) . Although osteoporotic fractures have long been associated with florid hyperthyroidism (4) and, more recently, with a history of hyperthyroidism in older women (5) , the relationship between biochemical evidence of excess thyroid hormone and fracture risk is not known (6, 7) .
Indirect evidence suggests that excess thyroid hormone due to endogenous disease or exogenous overuse of thyroid hormone may be associated with detrimental effects on bone, even in asymptomatic persons. For example, several biochemical markers of bone turnover are elevated in women with excess thyroid hormone (8, 9) . Findings from studies of the relationship between excess thyroid hormone and bone mass are conflicting (10 -17) . However, factors other than bone mass, such as neuromuscular function and bone quality, contribute to risk for fracture (5) and may be adversely affected by excess thyroid hormone. Results of previous small, retrospective studies of thyroid function and fractures have also been conflicting (18 -21) . To our knowledge, no large prospective studies have examined the relationship between excess thyroid hormone and subsequent fracture.
In light of the conflicting information on bone mass and the paucity of studies with fracture as an end point, several experts have noted the need for longitudinal studies of thyroid function and fracture risk (22) (23) (24) (25) (26) . To test the hypothesis that low levels of serum thyroidstimulating hormone (TSH) increase the risk for hip, vertebral, and any nonspine fracture, we performed a prospective study of postmenopausal women enrolled in the Study of Osteoporotic Fractures.
METHODS

Patients
The Study of Osteoporotic Fractures is a prospective cohort study of risk factors for fracture among 9704
Article women (5) . White women older than 65 years of age were recruited in 1986 to 1988 from population-based listings at four clinical centers (Portland, Oregon; Minneapolis, Minnesota; Pittsburgh, Pennsylvania; and Baltimore, Maryland). The institutional review boards of all four centers gave approval for this study involving human research subjects.
Measurements
Baseline Measurements
Participants were interviewed and examined during the baseline visit. Detailed information about physiciandiagnosed medical conditions and past medication use was collected, and trained interviewers confirmed current medication use by examination of pill bottles. Participants were asked specifically about self-rated health, previous physician diagnoses of hyperthyroidism or Graves disease, and previous use of thyroid hormone. In addition to standardized assessments of height and weight, bone mass of the calcaneus was determined by using single-photon absorptiometry (OsteoAnalyzer, Siemens-Osteon, Wahiawa, Hawaii) and lateral radiographs of the thoracic and lumbar spine were obtained (27, 28) . Serum was collected from each participant and stored at Ϫ190°C. Approximately 2 years after the baseline visit, bone mineral density of the proximal femur was measured in 82% of the cohort by using dualenergy x-ray absorbtiometry (Hologic QDR 1000, Waltham, Massachusetts) (29) .
Levels of TSH were measured in archived sera obtained at baseline by using a highly sensitive, third-generation chemiluminescent assay (Endocrine Science, Calabasas, California). The normal range for this assay is 0.5 to 5.5 mU/L; the functional sensitivity (defined as the concentration at which the interassay coefficient of variation is Ն20%) is approximately 0.05 mIU/L (30) . At TSH concentrations of 0.5 mIU/L, the intra-assay coefficient of variation is 4.7% and the interassay coefficient of variation is 6.3%. Thirty randomly selected specimens were blindly submitted for duplicate analysis; the correlation between these two TSH results was high (r ϭ 0.95). Previous studies have shown that TSH levels are highly stable in frozen sera over prolonged periods (31, 32) . Other studies have demonstrated that among ambulatory adults, TSH levels of 0.1 mIU/L or less are highly correlated with a diminished response to thyroidreleasing hormone stimulation (33) and are associated with an increased incidence of atrial fibrillation (34) .
Ascertainment of Incident Fractures
After the baseline visit, women were contacted by mail every 4 months about the occurrence of fractures. Hip fractures were confirmed by review of the appropriate radiographs by a radiologist at the coordinating center; other nonspine fractures were confirmed by review of written radiology reports. Fractures resulting from excessive trauma (such as motor vehicle accidents) were excluded. Follow-up for fracture and vital status was more than 99% complete.
Lateral spine radiographs were repeated in 7299 women (79% of surviving women) after a mean (ϮSD) follow-up of 3.7 Ϯ 0.4 years, and 7238 pairs of radiographs were judged to be adequate for assessment of incident vertebral fractures. Women without follow-up radiographs were older and reported poorer health at baseline compared with those who had follow-up radiographs (35) . Vertebral fractures were identified by using computer-assisted morphometric evaluation (36) , and incident vertebral fractures were defined as a 20% or greater and 4 mm or greater reduction in anterior, midvertebral, or posterior vertebral height between the baseline and follow-up radiographs (37) . The persons who assessed the radiographs had no knowledge of the participant's medical history or TSH level.
Selection of Case and Control Samples for Fracture Analyses
Using an efficient case-cohort approach that maintains statistical power but avoids expensive biochemical measurements in the entire cohort (38 -40), we randomly selected baseline serum samples from 148 women with hip fracture and 149 women with incident vertebral fracture after the baseline visit. We randomly selected 398 women from the original cohort, independent of fracture status, to be controls. This random sample, which we refer to as "the subsample" in this report, included 14 of the 148 women selected as incident hip fracture cases and 15 of the 149 women selected as incident vertebral fracture cases; these women were removed from the subsample and were analyzed as cases of hip and vertebral fracture, respectively. To create a fracture-free control group, we excluded women from the subsample with other nonspine fractures during follow-up (n ϭ 80 for the hip fracture analyses and n ϭ 58 for the vertebral fracture analyses). Ninety women in the subsample had missing or technically inadequate radiographs and could not be analyzed for vertebral fracture outcomes.
The analyses of any nonspine fracture were performed in the randomly selected subsample by using standard prospective cohort methods. After 14 women with unconfirmed fracture, 5 women with fracture from extreme trauma, and 6 women with spine fractures were excluded, the analysis of nonspine fracture included 100 women with documented nonspine fracture occurring after study entry and 273 without fracture. Random selection was done by using a computerized randomnumber generator.
Statistical Analysis
Continuous variables were plotted, and distributions, means, and standard deviations were examined. Levels of TSH were categorized as low (Յ0.1 mIU/L), borderline low (Ͼ0.1 but Ͻ0.5 mIU/L), normal (0.5 to 5.5 mIU/L), or high (Ͼ5.5 mIU/L).
Associations with hip fracture were examined by using proportional hazards analyses (Epicure, Hirosoft International, Seattle, Washington) that took into account the case-cohort sampling design. The proportionality assumption was not violated. Results are reported as relative hazards with 95% CIs. Logistic regression was used to analyze incident vertebral fracture; these results are reported as odds ratios with 95% CIs. Cox proportional hazards models were used to determine associations with nonspine fracture among the randomly selected subsample.
Multivariate models were constructed to adjust for potential confounders. Potential confounders were selected on the basis of biologic plausibility (for example, use of thyroid hormone) or a strong univariate association (P Յ 0.1) with TSH level (for example, age) or fracture (for example, estrogen use). We found no association (P Ͼ 0.1) between TSH level and maternal history of fracture, height, neuromuscular function, or corticosteroid use, which are known to be associated with fracture in this cohort (5) . The final multivariate models for each fracture type included TSH level, age, previous hyperthyroidism, self-rated health, and current use of thyroid hormone and estrogen.
To determine whether the increased risk for fracture in women with low TSH levels was mediated by reduced bone mass or some other mechanism, we examined the effect of further adjusting the final multivariate models for calcaneal bone mass measured at the baseline visit. The effect of adjustment for bone mineral density at the femoral neck, measured approximately 2 years after the baseline visit, was similar to that observed for calcaneal bone mineral density.
Role of the Funding Source
The funding source had no role in the collection, analysis, interpretation, or publication of these data.
RESULTS
During a maximum follow-up of 5.9 years, 332 women had a first hip fracture, 389 had an incident vertebral fracture detected on paired spinal radiographs, and 2520 had nonspine fractures. Women who had incident hip, vertebral, or any nonspine fractures were older and had lower bone mass than controls ( Table 1) . Women with hip fractures were more likely to report previous hyperthyroidism. Mean TSH levels were similar among women with and without fracture, but the proportion of women with a low TSH level (Յ0.1 mIU/L) was significantly greater among those with hip or vertebral fracture. Overall, 11% of participants reported thyroid hormone use at the baseline visit, whereas 86% of women with low TSH levels reported thyroid hormone use. Among the 42 women with TSH levels of 0.1 mIU/L or less, 29 (69%) had levels of 0.05 mIU/L or less.
TSH Level and Hip Fracture
The risk for hip fracture during follow-up was more than threefold higher among women with low TSH levels than those with normal TSH levels ( Table 2) . Adjustment for age, previous hyperthyroidism, self-rated health, and current use of estrogen and thyroid hormone had little effect. Additional adjustment for body weight, which was lower in women with hip fracture and is likely to be mediated by excess thyroid hormone, had minimal effect on the relationship between low TSH level and hip fracture (relative hazard, 3.2 [95% CI, 0.9 to 11.6]). After further adjustment for calcaneal bone mineral density, the risk for new hip fracture was still elevated among women with low TSH levels, but the relationship was no longer statistically significant (relative hazard ratio, 2.3 [CI, 0.6 to 8.5]).
Relative to women with normal TSH levels, the risk for hip fracture was not significantly increased among women with borderline low TSH levels (0.1 to 0.5 mIU/L) ( Table 2) .
TSH Level and Vertebral Fracture
The risk for new (incident) vertebral fracture during follow-up was threefold higher among women with low TSH levels than those with normal TSH levels ( Table  3) . After adjustment for age, previous hyperthyroidism, self-rated health status, and current use of estrogen and thyroid hormone, the risk for new vertebral fracture was more than fourfold greater in women with low TSH levels. Additional adjustment for body weight, which was lower in women with incident vertebral fractures, slightly reduced the strength of the association between low TSH level and fracture (odds ratio, 4.1 [CI, 1.2 to 14.3]). After further adjustment for calcaneal bone mineral density, the risk for new vertebral fracture was still elevated among women with low TSH levels, but the relationship was no longer statistically significant (odds ratio, 3.1 [CI, 0.9 to 11.2]).
After adjustment for potential confounders, the risk for vertebral fracture was nearly threefold greater among women with borderline low TSH levels than among those with normal TSH levels ( Table 3) .
TSH Level and Nonspine Fracture
Compared with women who had normal TSH levels, women with low TSH levels at the baseline visit had a twofold greater risk for any nonspine fracture during follow-up ( Table 4) . After adjustment for potential confounders, the magnitude of this association was unchanged, but it was no longer statistically significant (relative hazard ratio, 2.2 [CI, 0.8 to 6.6]).
Previous Hyperthyroidism, Thyroid Hormone Use, and Fracture Risk
The risk for hip fracture was twofold higher among women with a history of hyperthyroidism ( Article Low Serum Levels of Thyroid-Stimulating Hormone and Risk for Fracture bone mineral density did not alter the relationship between previous hyperthyroidism and hip fracture (relative hazard, 2.5 [CI, 1.1 to 5.4]). Previous hyperthyroidism was not associated with increased risk for vertebral fracture ( Table 3 ) or nonspine fracture ( Table 4) . Thyroid hormone use was not associated with increased risk for hip, vertebral, or any nonspine fracture in unadjusted analyses, and results were similar after adjustment for TSH level, age, previous hyperthyroidism, self-rated health, and current estrogen use (Tables 2, 3 , and 4).
DISCUSSION
In this large prospective study of thyroid function and subsequent fracture among women older than 65 years of age, those with TSH levels of 0.1 mIU/L or less had a significantly increased risk for new hip and vertebral fractures. This adverse effect was independent of age, previous hyperthyroidism, self-rated health, and use of estrogen and thyroid hormone. The risk for vertebral fracture, but not hip or other nonspine fracture, was significantly elevated among women with borderline low TSH levels (0.1 to 0.5 mIU/L). Women who reported previous hyperthyroidism had an increased risk for hip fracture, but we found no evidence that thyroid hormone use itself was associated with an increased risk of fracture.
The relationship between excess thyroid hormone and osteoporosis has been controversial. Although overt hyperthyroidism is associated with osteoporosis (41-43), previous studies have produced conflicting data on the effect of excess thyroid hormone and bone mass (10, 11, 15, 16) or bone loss (31, 44) . Biochemical markers of bone turnover, such as serum osteocalcin and urine N-teleopeptide of type 1 collagen, are elevated in persons with evidence of excess thyroid hormone (8, 9, 45) . Some studies have found that elevated levels of biochemical markers of bone turnover are associated with increased risk for fracture independent of bone mineral density (46, 47) .
Relatively few studies have examined the relation between excess thyroid hormone and fractures. An older study (18) found no significant overall increase in the rate of fracture among 306 women with treated hyperthyroidism compared with age-matched controls. A more recent study (20) found that thyroid hormone users with low TSH levels (Ͻ0.05 mIU/L) did not have an increased rate of hospitalization for fracture compared with persons who had normal TSH levels. Of note, in that study, the risk for hospitalization because of fracture was approximately twofold greater in persons older than 65 years of age with low TSH levels. Another retrospective study (19) found that women with a history of hyperthyroidism or thyroid cancer appeared to have their first fracture earlier than women without thyroid disease, and two recent case-control studies of endogenous hyperthyroidism and fracture had conflicting results (21, 48) .
We previously reported that a history of hyperthyroidism was associated with increased risk for hip fracture in the full Study of Osteoporotic Fractures cohort (5). The current study confirms the adverse skeletal consequences of previous hyperthyroidism and extends our previous findings in that the relationship between previous hyperthyroidism and hip fracture seems to be independent of TSH level and calcaneal bone mineral density. These data raise the possibility that the longterm adverse skeletal effects of endogenous hyperthyroidism (or its treatment) are not mediated by persistent hyperthyroidism or reduced bone mass. Conversely, adjustment for baseline calcaneal bone density attenuated the relationship between low TSH level and fracture, suggesting that low TSH may increase fracture risk in part by reducing bone mass. Further studies are necessary to determine whether other mechanisms, such as poor bone quality from accelerated remodeling, explain these observations. Compared with previous studies, our prospective study had several important strengths: It was larger, used population-based sampling, carefully documented potential confounders (such as estrogen use and previous hyperthyroidism), followed participants over an extended period, and adjudicated fractures by using objective and validated methods. Biochemical markers of bone turnover were elevated in women with low TSH levels in this sample (44) , supporting the view that low TSH levels reflect excessive thyroid hormone, which in turn increases skeletal remodeling (49) .
Our study also had limitations. Because of insufficient sera, we could not measure thyroxine or triidothyronine levels in women with low TSH levels, and we therefore could not determine the independent effect of thyroid hormone levels on risk for fracture. Other studies have demonstrated that most persons with low but detectable TSH levels while taking exogenous thyroid have normal thyroid hormone levels, and nearly half of those with TSH levels of 0.05 mIU/L or less have normal thyroid hormone levels (50). In our study, 69% of women with low TSH levels had levels less than 0.05 mIU/L, and too few fractures occurred to allow separate analysis of women with TSH levels between 0.05 and 0.1 mIU/L. Further study of risk for fracture among women with low TSH levels but normal thyroid hormone levels is needed. Levels of TSH were measured only once, and some women may have had transiently low levels; however, a second TSH measurement would probably only have strengthened the observed association between low TSH and fracture. In addition, we cannot rule out the possibility that a small number of women in our cohort had low TSH levels as a result of severe medical or psychiatric illness (51) , but the adverse effects of low TSH persisted after adjustment for selfrated health. Thyroid-stimulating hormone was measured in sera that had been archived for approximately 6 to 8 years at Ϫ190°C; although the effects of long-term storage at these temperatures have not been studied, the TSH levels reported in this study were similar to those in other similar older cohorts (52) . Finally, most of the study participants were older women, and 86% of those with low TSH levels were taking thyroid hormone; generalization of these results to other populations must be done with caution.
Because this was an observational study, we could not rule out the possibility that low TSH levels might have been a physiologic marker for increased fracture risk for reasons other than physiologic hyperthyroidism. A randomized clinical trial in which TSH were normalized in one group and not in another group would be necessary. Likewise, our study provides no direct information on whether normalization of TSH level would reduce risk for fracture among women with low bone mineral density who are taking thyroid hormone replacement. However, if physiologic hyperthyroidism contributes to increased skeletal fragility and increased risk for fracture, a lower dose of hormone might be beneficial. Finally, our study does not indicate whether normalization of TSH level is more or less effective than therapies aimed at reducing the risk for fracture by increasing bone mineral density or preventing bone loss. However, since decreasing the dose of thyroid hormone to normalize the TSH level has no known adverse effects, our findings suggest that a prudent clinical course of action may be to maintain TSH levels in the normal range. Furthermore, use of suppressive thyroid hormone therapy for benign conditions should be reconsidered in light of the adverse skeletal consequences of low TSH level. Our findings suggest that thyroid hormone use itself is not associated with an increased risk for fracture. Although the majority of women with low TSH levels in this study were taking thyroid hormone, those with normal TSH levels while taking thyroid hormone did not have an increased risk for fracture.
In conclusion, we found that older women with biochemical evidence of excess thyroid hormone have an increased risk for hip and vertebral fractures. We found no evidence that thyroid hormone use itself adversely effects fracture rates if TSH levels are normal, but previous hyperthyroidism is independently associated with an increased risk for hip fracture, even after adjustment for TSH levels and bone mineral density. Additional studies are needed to determine whether these findings apply equally to women not taking thyroid hormone or whether the increased risk for fracture is limited to those with elevated levels of thyroid hormone.
